Ionis Pharmaceuticals Stock Plunges 28% to Worst Day Since 2016 as Company Halves Tryngolza Sales Forecast
Ionis Pharmaceuticals' stock fell 28% after halving its 2026 sales forecast for Tryngolza, its triglyceride-lowering drug, despite beating Q3 earnings expectations. The company cited a slower-than-expected launch ramp. Q3 revenue was $243M, up 55% YoY, with a net loss of $110M. Ionis maintained its full-year revenue guidance of $875M-$900M.
How this was made
The 30-second read
Why it matters
The guidance cut is a fresh, material disclosure that drove a 28% intraday decline, indicating heightened downside risk.
Market read
The stock's sharp drop and guidance reduction make this a high‑impact, actionable event for traders.
What to watch
Ionis maintains total revenue guidance and non‑GAAP loss guidance, which may cushion the impact.
Background
Ionis reported Q3 results that beat revenue expectations, but sharply reduced guidance for its flagship triglyceride‑lowering drug Tryngolza.
Ticker impact
Ionis Pharmaceuticals cut full-year 2026 Tryngolza sales guidance by ~52% to about $50M, triggering a 28% share plunge.
downward pressure as investors price in lower sales outlook
Guidance cut is a material new fact; the stock already fell 28% on the news, suggesting continued sell pressure.
Market effects
Biotech sector may see broader risk-off as guidance cuts raise concerns about commercial execution.
US biotech stocks could face short-term weakness.
Limited to investors with exposure to Ionis and similar lipid‑lowering drug developers.
Counterpoint
If the broader pipeline delivers strong data, the stock could rebound from an over‑reacted sell‑off.
Key entities
- companyIonis Pharmaceuticals Inc.
US‑listed biotech developing lipid‑lowering therapies.
